DRUG · Unmapped registry intervention
MM-121
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
NCT00994123
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Erlotinib
Normalized identity: erlotinibView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Interventions
MM-121DRUG
ErlotinibDRUG · verified · RxNorm: erlotinib
Sponsors & collaborators
Merrimack Pharmaceuticalslead sponsor
Mapped research locations
TaichungTaiwan2New YorkNew York, United States1BostonMassachusetts, United States1DallasTexas, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1TorontoOntario, Canada1NashvilleTennessee, United States1San FranciscoCalifornia, United States1MadridSpain1BarcelonaSpain1PittsburghPennsylvania, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00994123 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.